围手术期静脉血栓栓塞症形成风险评估及抗凝药物管理

摘要/Abstract

中图分类号:

R559

毛毅敏, 黄伸伸, 和雪改. 围手术期静脉血栓栓塞症形成风险评估及抗凝药物管理[J]. 诊断学理论与实践, 2019, 18(1): 16-20.

参考文献26

[1]	Zhai Z, Kan Q, Li W, et al. VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients: The Identification of Chinese Hospitalized Patients′ Risk Profile for Venous Thromboembolism (DissolVE-2)-A Cross-sectional Study[J]. Chest, 2019, 155(1):114-122.
[2]	Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study[J]. Lancet, 2008, 371(9610):387-394.
[3]	中华医学会骨科学分会. 中国骨科大手术静脉血栓栓塞症预防指南[J]. 中华骨科杂志, 2009, 29(6):602-604.
[4]	中华医学会血栓栓塞性疾病防治委员会. 医院内静脉血栓栓塞症预防与管理建议[J]. 中华医学杂志, 2012, 92(40):2816-2819.
[5]	中华医学会外科学分会. 中国普通外科围手术期血栓预防与管理指南[J]. 中华外科杂志, 2016, 54(5):321-327.
[6]	中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组. 肺血栓栓塞症诊治与预防指南[J]. 中华医学杂志, 2018, 98(14):1060-1087.
[7]	Sobel M, Verhaeghe R. Verhaeghe. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)[J]. Chest, 2008, 133(6 Suppl):815S-843S.
[8]	Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141(2 Suppl):e669S-e690S.
[9]	《中国血栓性疾病防治指南》专家委员会. 中国血栓性疾病防治指南[J]. 中华医学杂志, 2018, 98(36):2861-2888.
[10]	Autar R. Nursing assessment of clients at risk of deep vein thrombosis (DVT): the Autar DVT scale[J]. J Adv Nurs, 1996, 23(4):763-770.
[11]	Liu X, Liu C, Chen X, et al. Comparison between Caprini and Padua risk assessment models for hospitalized medical patients at risk for venous thromboembolism: a retrospective study[J]. Interact Cardiovasc Thorac Surg, 2016, 23(4):538-543.
[12]	Bahl V, Hu HM, Henke PK, et al. A validation study of a retrospective venous thromboembolism risk scoring method[J]. Ann Surg, 2010, 251(2):344-350.
[13]	Zhou H, Wang L, Wu X, et al. Validation of a venous thromboembolism risk assessment model in hospitalized chinese patients: a case-control study[J]. J Atheroscler Thromb, 2014, 21(3):261-272.
[14]	郎景和, 王辰, 瞿红, 等. 妇科手术后深静脉血栓形成及肺栓塞预防专家共识[J]. 中华妇产科杂志, 2017, 52(10):649-653.
[15]	李辉, 姜格宁, 中国胸外科静脉血栓栓塞症研究协作组. 胸部恶性肿瘤围术期静脉血栓栓塞症预防中国专家共识(2018版)[J]. 中国肺癌杂志, 2018, 21(10):739-752.
[16]	Büyükyülmaz F, Sçendir M, Autar R, et al. Risk level analysis for deep vein thrombosis (DVT): A study of Turkish patients undergoing major orthopedic surgery[J]. J Vasc Nurs, 2015, 33(3):100-105.
[17]	Rogers SO Jr, Kilaru RK, Hosokawa P, et al. Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery: results from the patient safety in surgery study[J]. J Am Coll Surg, 2007, 204(6):1211-1221.
[18]	田博, 宋春凤, 李辉, 等. Caprini和Rogers风险评估模型联合使用可以提高胸外科术后患者筛选静脉血栓栓塞症的准确性[J]. 中华胸部外科电子杂志, 2017, 4(3):186-189.
[19]	《中国血栓性疾病防治指南》专家委员会. 中国血栓性疾病防治指南[J]. 中华医学杂志, 2018, 98(36):2861-2888.
[20]	Imberti D, Ambrosoli A, Cimminiello C, et al. Periprocedural management of rivaroxaban-treated patients[J]. Expert Opin Pharmacother, 2015, 16(5):685-691.
[21]	K Kkinen, R Cartwright, G Guyatt. EAU Guidelines on Thromboprophylaxis in Urological Surgery[EB/OL].( 2017-07-01)[2019-01-20]. , 2017.
[22]	Smith M, Wakam G, Wakefield T, et al. New Trends in Anticoagulation Therapy[J]. Surg Clin North Am, 2018, 98(2):219-238.
[23]	Cerfolio RJ, Bryant AS. The management of anticoagulants perioperatively[J]. Thorac Surg Clin, 2012, 22(1):29-34.
[24]	Doonquah L, Mitchell A D. Oral surgery for patients on anticoagulant therapy: current thoughts on patient management[J]. Dent Clin North Am, 2012, 56(1):25-41.
[25]	Matsuoka T, Inoue K, Mizuno K, et al. Heparin as bridging anticoagulant and antiplatelet therapy during the perioperative period[J]. Hinyokika Kiyo, 2012, 58(5):223-226.
[26]	Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT)[J]. J Thromb Haemost, 2007, 5(11):2211-2218.

围手术期静脉血栓栓塞症形成风险评估及抗凝药物管理

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献26

相关文章6

编辑推荐

Metrics

本文评价

[1]	开云网页登录医学院附属瑞金医院肺小结节诊治和管理学科群专家组.肺结节活检术风险管理瑞金专家共识[J]. 诊断学理论与实践, 2022, 21(01): 22-31.
[2]	陈信光, 张凤祥.特定人群室性心律失常风险评估进展及策略[J]. 诊断学理论与实践, 2020, 19(06): 549-554.
[3]	刘彤, 王鑫.心房颤动预后不良风险的评估策略[J]. 诊断学理论与实践, 2020, 19(06): 555-558.
[4]	武冬冬, 胡夏生, 刘银红, 蒋景文.脑微出血的临床意义及其伴心房颤动时的抗凝治疗决策进展[J]. 诊断学理论与实践, 2020, 19(05): 534-539.
[5]	林建华, 缪慧娴.妊娠合并心脏病的分类诊断和妊娠风险评估[J]. 诊断学理论与实践, 2019, 18(06): 613-618.
[6]	俞庆宪, 吴云林,.74例老年进展期胃癌营养状况评估与研究[J]. 诊断学理论与实践, 2014, 13(06): 620-621.